Non-Small Cell Lung CancerPhase 1/2NCT07632365
Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
A Phase 1/2 study testing Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT) and consolidation immunotherapy in people with Non-Small Cell Lung Cancer and Locally Advanced Non-Small Cell Lung Cancer, run by Shanghai Chest Hospital at 1 site in China.
Trial summary
PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
- What is being tested?
- Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT) and consolidation immunotherapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- 1 siteChina
- Study dates
- 9 Oct 2022to 31 Dec 2028
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >18 years, male or female, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
- Unresectable stage III NSCLC (according to the 8th edition of the AJCC staging system).
- No prior exposure to any other anti-tumor therapy.
- Absence of severe medical comorbidities or major organ dysfunction, as assessed by hematology, hepatic, renal, cardiac, and pulmonary function tests, meeting the following criteria: Hematology: Hemoglobin (HB) ≥ 90 g/L (without blood transfusion within 14 days prior to enrollment); absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count (PLT) ≥ 100 × 10⁹/L. Biochemistry: Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum creatinine (Cr) ≤ 1 × ULN, with an endogenous creatinine clearance rate > 60 mL/min (calculated using the Cockcroft-Gault formula). Coagulation: Prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless the patient is receiving anticoagulant therapy, in which case PT or aPTT must be within the expected therapeutic range for the anticoagulant used).
- Life expectancy ≥ 3 months.
- Adequate understanding of the study, ability to complete treatment, suitability for follow-up, and voluntary provision of written informed consent.
Who cannot join
- Presence of small cell carcinoma components in the histological examination results.
- Co-occurrence of EGFR mutation, ALK rearrangement, or ROS-1 rearrangement positivity.
- History of other primary malignancies, with the following exceptions: Malignancies treated with curative intent with no known active disease and low potential for recurrence for ≥5 years prior to the first dose of investigational product (IP); adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; or adequately treated carcinoma in situ without evidence of disease.
- Active or documented history of autoimmune or inflammatory diseases (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [excluding diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, granulomatosis with polyangiitis [Wegener's syndrome], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.).
- History of allogeneic organ transplantation.
- History of active primary immunodeficiency.
Show all 11Show fewer
- Presence of uncontrolled concurrent illness, including but not limited to persistent or active infection (including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus [HIV], etc.), symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease (ILD), severe chronic gastrointestinal disease associated with diarrhea, or psychiatric disorders/social situations that would limit compliance with study requirements, substantially increase the risk of adverse events (AEs), or compromise the patient's ability to provide written informed consent.
- Female patients who are pregnant or breastfeeding.
- Concurrent or prior use of immunosuppressive medication within 14 days prior to the first dose of induction immunotherapy. Exceptions include: intranasal, inhaled, or topical corticosteroids, or local corticosteroid injections (e.g., intra-articular injection); systemic corticosteroids at physiological doses not exceeding 10 mg/day of prednisone or its equivalent; corticosteroids as prophylactic premedication for hypersensitivity reactions (e.g., premedication for computed tomography [CT] scan); or systemic corticosteroid administration administered as part of chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC), or administered prophylactically or for the management of toxicity induced by chemotherapy and/or radiotherapy.
- Known allergy or hypersensitivity to any study drug or any excipient of a study drug.
- Patients judged by the investigator to be unable to comply with study procedures, restrictions, and requirements.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Shanghai Chest Hospital
Shanghai, Xuhui, 200030
15800524839@163.com
Wen Yu, MD
About this study
Official title: A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Induction Chemoimmunotherapy Followed by Concurrent Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Phase I consists of a single-arm safety lead-in study evaluating the safety and preliminary efficacy of the investigational regimen. If predefined safety criteria are met, the study proceeds to a phase II randomized controlled trial comparing induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy with the standard PACIFIC regimen. The objective of the phase II study is to determine whether the investigational treatment strategy improves progression-free survival while maintaining an acceptable safety profile compared with the standard PACIFIC regimen.
Read the detailed description
Concurrent chemoradiotherapy followed by consolidation immunotherapy has become the standard treatment approach for unresectable locally advanced NSCLC based on the PACIFIC study. However, disease recurrence remains common, and long-term progression-free survival remains unsatisfactory. Strategies to further improve outcomes and optimize the integration of systemic therapy and radiotherapy are still needed.
Induction chemoimmunotherapy has demonstrated significant tumor regression and downstaging effects in locally advanced NSCLC. Tumor burden reduction achieved during induction treatment may improve radiotherapy feasibility, enhance target conformity, reduce radiation exposure to surrounding normal tissues, and potentially improve the therapeutic effectiveness of subsequent radiotherapy.We also hypothesize that induction chemoimmunotherapy can achieve early immune activation, thereby enhancing the synergy between subsequent chemoradiotherapy and immunotherapy and potentially improving the survival outcomes of the current PACIFIC treatment paradigm.
This multicenter phase I/II study consists of two sequential parts. The phase I portion is designed as a single-arm safety lead-in study evaluating induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy. If predefined safety criteria are met, the study proceeds to a phase II randomized, open-label, parallel-group trial in which eligible participants are randomized in a 1:1 ratio to receive either induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy or the standard PACIFIC regimen consisting of concurrent chemoradiotherapy followed by consolidation immunotherapy. Randomization is stratified by disease stage (IIIA vs. IIIB/IIIC) and PD-L1 tumor cell expression (<1% vs. ≥1%). The objective of this study is to determine whether the addition of induction chemoimmunotherapy to the standard PACIFIC treatment strategy improves progression-free survival while maintaining an acceptable safety profile.
For the phase I safety lead-in study, the co-primary endpoints are treatment safety, assessed by the incidence of grade 3 or higher treatment-related adverse events, and progression-free survival (PFS). For the phase II randomized study, the primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), treatment completion rate, local control rate, and treatment-related adverse events. Exploratory analyses include evaluation of minimal residual disease (MRD) to determine whether baseline and dynamic changes in MRD status are associated with treatment response, progression-free survival, and overall survival in participants receiving combined radiotherapy and immunotherapy.
- Conditions
- Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
- Being tested
- Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy
- Keywords
- NSCLC, Stage III NSCLC, Unresectable NSCLC, Concurrent Chemoradiotherapy, Consolidation Immunotherapy, Chemoimmunotherapy, PD-1 Inhibitor, PACIFIC Regimen
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Induction chemoimmunotherapyDrug
Phase I: Patients received platinum-based doublet chemotherapy plus a PD-L1 inhibitor every 3 weeks for 2-4 cycles. Phase II (experimental group): Patients received platinum-based doublet chemotherapy plus a PD-L1 inhibitor every 3 weeks for 2 cycles.
Concurrent chemoradiotherapy (cCRT)Radiation
Definitive thoracic radiotherapy delivered to the primary tumor and involved lymph nodes with concurrent platinum-based chemotherapy. Radiotherapy is administered at 50-60 Gy in 25-30 fractions using intensity-modulated radiotherapy techniques.
consolidation immunotherapyDrug
PD-L1 inhibitor administered every 3 weeks after completion of radiotherapy for up to 1 year or until disease progression, unacceptable toxicity, or withdrawal of consent.
| Study group | Role | What they receive |
|---|---|---|
| Phase I Safety Lead-in Cohort/Phase II Experimental Arm (CI-CCRT-I Strategy) | Experimental | Participants will receive induction chemoimmunotherapy followed by definitive concurrent chemoradiotherapy and consolidation immunotherapy. Induction treatment consists of two cycles (2-4 cycles in phase I cohort) of platinum-based chemotherapy combined with PD-L1 inhibitor prior to concurrent chemoradiotherapy. Participants without disease progression after concurrent chemoradiotherapy will subsequently receive consolidation PD-L1 inhibitor for up to one year or until disease progression or unacceptable toxicity. Receives: Drug: Induction chemoimmunotherapy; Radiation: Concurrent chemoradiotherapy (cCRT); Drug: consolidation immunotherapy |
| Phase II Control Arm (PACIFIC Strategy) | Active comparator | Participants will receive definitive concurrent chemoradiotherapy followed by consolidation PD-L1 inhibitor according to the standard PACIFIC treatment strategy. Participants without disease progression after concurrent chemoradiotherapy will receive consolidation PD-L1 inhibitor for up to one year or until disease progression or unacceptable toxicity. Receives: Radiation: Concurrent chemoradiotherapy (cCRT); Drug: consolidation immunotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Grade 3 or Higher Treatment-Related Adverse Events
Treatment-related adverse events assessed according to CTCAE version 6.0.
Measured: From treatment initiation through 6 months after completion of radiotherapy
Progression-Free Survival (PFS)
Progression-free survival is defined as the time from treatment initiation to documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
Measured: Up to 36 months
Secondary outcomes (4)
Overall Survival (OS)
Overall survival is defined as the time from treatment initiation to death from any cause.
Measured: Up to 60 months
Objective Response Rate (ORR)
Objective response rate is defined as the proportion of participants achieving complete response (CR) or partial response (PR) according to RECIST version 1.1.
Measured: From baseline through 24 months
Treatment Completion Rate
Proportion of participants who successfully complete the planned induction chemoimmunotherapy, radiotherapy-based treatment (concurrent chemoradiotherapy or carbon-ion radiotherapy), and consolidation immunotherapy according to protocol requirements.
Measured: Up to 18 months
Local Control Rate
Local control rate is defined as the proportion of participants without locoregional disease progression according to RECIST version 1.1 and investigator assessment.
Measured: Up to 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start9 Oct 2022
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Non-Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Shanghai Chest HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is an open-label, multicenter, phase I/II interventional study. Phase I consists of a single-arm safety lead-in cohort evaluating induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy (CI-CCRT-I). If predefined safety criteria are met, the study proceeds to a phase II randomized, parallel-group trial. In the phase II study, eligible participants are randomized in a 1:1 ratio to receive either induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy (investigational arm) or concurrent chemoradiotherapy followed by consolidation immunotherapy according to the standard PACIFIC regimen (control arm). Randomization is stratified by disease stage (IIIA vs. IIIB/IIIC) and PD-L1 tumor cell expression (\<1% vs. ≥1%).
- Masking
- None (open label)
- Enrolment
- 108 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shanghai Chest Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Sun Yat-Sen University Cancer Center, RenJi Hospital
- Responsible party
- Principal investigator, Wen Yu, Shanghai Chest Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07632365
- Sponsor's protocol ID
- PIVOT
- Status last verified
- Jul 2026
- First submitted
- 3 Jun 2026
- Last updated
- 23 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Wang Y, Zhang T, Wang J, Zhou Z, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Ma X, Xue Q, Wang J, Wang Z, Bi N. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):590-600. doi: 10.1016/j.ijrobp.2022.12.042. Epub 2023 Jan 7.
PubMed 36623605Heymach JV, Harpole D, Mitsudomi T ea. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. 2023 AACR Annual Meeting; April 14-19, 2023; Orlando, FL 2023;
Wang C, Chen KN, Chen Q, Wu L, Wang Q, Li X, Ying K, Wang W, Zhao J, Liu L, Fu J, Zhang C, Liu J, Hu Y, Ntambwe I, Cai J, Bushong J, Tran P, Lu S. Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816. ESMO Open. 2023 Dec;8(6):102040. doi: 10.1016/j.esmoop.2023.102040. Epub 2023 Nov 1.
PubMed 37922691Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. Online ahead of print.
PubMed 34086039Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.
PubMed 35038429Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Ozguroglu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.
PubMed 35108059Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. doi: 10.1093/jnci/djr325. Epub 2011 Sep 8.
PubMed 21903745Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
PubMed 33538338
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Induction Chemoimmunotherapy Followed by Concurrent Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT07632365
- Acronym / sponsor ID
- PIVOT
- Conditions
- Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLC
- Keywords
- NSCLC, Stage III NSCLC, Unresectable NSCLC, Concurrent Chemoradiotherapy, Consolidation Immunotherapy, Chemoimmunotherapy, PD-1 Inhibitor, PACIFIC Regimen
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 108 participants (estimated)
- Lead sponsor
- Shanghai Chest HospitalUniversity, hospital or other
- Collaborators
- Sun Yat-Sen University Cancer Center, RenJi Hospital
- Study start
- 9 Oct 2022 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PIVOT study is a multicenter, phase I/II clinical study designed to evaluate induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Phase I consists of a single-arm safety lead-in study evaluating the safety and preliminary efficacy of the investigational regimen. If predefined safety criteria are met, the study proceeds to a phase II randomized controlled trial comparing induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy with the standard PACIFIC regimen. The objective of the phase II study is to determine whether the investigational treatment strategy improves progression-free survival while maintaining an acceptable safety profile compared with the standard PACIFIC regimen.
Detailed description
Concurrent chemoradiotherapy followed by consolidation immunotherapy has become the standard treatment approach for unresectable locally advanced NSCLC based on the PACIFIC study. However, disease recurrence remains common, and long-term progression-free survival remains unsatisfactory. Strategies to further improve outcomes and optimize the integration of systemic therapy and radiotherapy are still needed.
Induction chemoimmunotherapy has demonstrated significant tumor regression and downstaging effects in locally advanced NSCLC. Tumor burden reduction achieved during induction treatment may improve radiotherapy feasibility, enhance target conformity, reduce radiation exposure to surrounding normal tissues, and potentially improve the therapeutic effectiveness of subsequent radiotherapy.We also hypothesize that induction chemoimmunotherapy can achieve early immune activation, thereby enhancing the synergy between subsequent chemoradiotherapy and immunotherapy and potentially improving the survival outcomes of the current PACIFIC treatment paradigm.
This multicenter phase I/II study consists of two sequential parts. The phase I portion is designed as a single-arm safety lead-in study evaluating induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy. If predefined safety criteria are met, the study proceeds to a phase II randomized, open-label, parallel-group trial in which eligible participants are randomized in a 1:1 ratio to receive either induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy or the standard PACIFIC regimen consisting of concurrent chemoradiotherapy followed by consolidation immunotherapy. Randomization is stratified by disease stage (IIIA vs. IIIB/IIIC) and PD-L1 tumor cell expression (<1% vs. ≥1%). The objective of this study is to determine whether the addition of induction chemoimmunotherapy to the standard PACIFIC treatment strategy improves progression-free survival while maintaining an acceptable safety profile.
For the phase I safety lead-in study, the co-primary endpoints are treatment safety, assessed by the incidence of grade 3 or higher treatment-related adverse events, and progression-free survival (PFS). For the phase II randomized study, the primary endpoint is progression-free survival (PFS). Secondary endpoints include overall survival (OS), objective response rate (ORR), treatment completion rate, local control rate, and treatment-related adverse events. Exploratory analyses include evaluation of minimal residual disease (MRD) to determine whether baseline and dynamic changes in MRD status are associated with treatment response, progression-free survival, and overall survival in participants receiving combined radiotherapy and immunotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is an open-label, multicenter, phase I/II interventional study. Phase I consists of a single-arm safety lead-in cohort evaluating induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy (CI-CCRT-I). If predefined safety criteria are met, the study proceeds to a phase II randomized, parallel-group trial. In the phase II study, eligible participants are randomized in a 1:1 ratio to receive either induction chemoimmunotherapy followed by concurrent chemoradiotherapy and consolidation immunotherapy (investigational arm) or concurrent chemoradiotherapy followed by consolidation immunotherapy according to the standard PACIFIC regimen (control arm). Randomization is stratified by disease stage (IIIA vs. IIIB/IIIC) and PD-L1 tumor cell expression (<1% vs. ≥1%).
| Arm | Type | Receives |
|---|---|---|
| Phase I Safety Lead-in Cohort/Phase II Experimental Arm (CI-CCRT-I Strategy) | Experimental | Drug: Induction chemoimmunotherapy, Radiation: Concurrent chemoradiotherapy (cCRT), Drug: consolidation immunotherapyParticipants will receive induction chemoimmunotherapy followed by definitive concurrent chemoradiotherapy and consolidation immunotherapy. Induction treatment consists of two cycles (2-4 cycles in phase I cohort) of platinum-based chemotherapy combined with PD-L1 inhibitor prior to concurrent chemoradiotherapy. Participants without disease progression after concurrent chemoradiotherapy will subsequently receive consolidation PD-L1 inhibitor for up to one year or until disease progression or unacceptable toxicity. |
| Phase II Control Arm (PACIFIC Strategy) | Active comparator | Radiation: Concurrent chemoradiotherapy (cCRT), Drug: consolidation immunotherapyParticipants will receive definitive concurrent chemoradiotherapy followed by consolidation PD-L1 inhibitor according to the standard PACIFIC treatment strategy. Participants without disease progression after concurrent chemoradiotherapy will receive consolidation PD-L1 inhibitor for up to one year or until disease progression or unacceptable toxicity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age >18 years, male or female, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
- Unresectable stage III NSCLC (according to the 8th edition of the AJCC staging system).
- No prior exposure to any other anti-tumor therapy.
- Absence of severe medical comorbidities or major organ dysfunction, as assessed by hematology, hepatic, renal, cardiac, and pulmonary function tests, meeting the following criteria: Hematology: Hemoglobin (HB) ≥ 90 g/L (without blood transfusion within 14 days prior to enrollment); absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count (PLT) ≥ 100 × 10⁹/L. Biochemistry: Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum creatinine (Cr) ≤ 1 × ULN, with an endogenous creatinine clearance rate > 60 mL/min (calculated using the Cockcroft-Gault formula). Coagulation: Prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN (unless the patient is receiving anticoagulant therapy, in which case PT or aPTT must be within the expected therapeutic range for the anticoagulant used).
Key exclusion criteria (11 listed)
- Presence of small cell carcinoma components in the histological examination results.
- Co-occurrence of EGFR mutation, ALK rearrangement, or ROS-1 rearrangement positivity.
- History of other primary malignancies, with the following exceptions: Malignancies treated with curative intent with no known active disease and low potential for recurrence for ≥5 years prior to the first dose of investigational product (IP); adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; or adequately treated carcinoma in situ without evidence of disease.
- Active or documented history of autoimmune or inflammatory diseases (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [excluding diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, granulomatosis with polyangiitis [Wegener's syndrome], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.).
- History of allogeneic organ transplantation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Induction chemoimmunotherapyPhase I: Patients received platinum-based doublet chemotherapy plus a PD-L1 inhibitor every 3 weeks for 2-4 cycles. Phase II (experimental group): Patients received platinum-based doublet chemotherapy plus a PD-L1 inhibitor every 3 weeks for 2 cycles. | Drug | Phase I Safety Lead-in Cohort/Phase II Experimental Arm (CI-CCRT-I Strategy) |
| Concurrent chemoradiotherapy (cCRT)Definitive thoracic radiotherapy delivered to the primary tumor and involved lymph nodes with concurrent platinum-based chemotherapy. Radiotherapy is administered at 50-60 Gy in 25-30 fractions using intensity-modulated radiotherapy techniques. | Radiation | Phase I Safety Lead-in Cohort/Phase II Experimental Arm (CI-CCRT-I Strategy), Phase II Control Arm (PACIFIC Strategy) |
| consolidation immunotherapyPD-L1 inhibitor administered every 3 weeks after completion of radiotherapy for up to 1 year or until disease progression, unacceptable toxicity, or withdrawal of consent. | Drug | Phase I Safety Lead-in Cohort/Phase II Experimental Arm (CI-CCRT-I Strategy), Phase II Control Arm (PACIFIC Strategy) |
Primary outcome
Incidence of Grade 3 or Higher Treatment-Related Adverse Events
Time frame: From treatment initiation through 6 months after completion of radiotherapy
Treatment-related adverse events assessed according to CTCAE version 6.0.
Progression-Free Survival (PFS)
Time frame: Up to 36 months
Progression-free survival is defined as the time from treatment initiation to documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.
4 secondary outcomes
Overall Survival (OS)
Time frame: Up to 60 months
Objective Response Rate (ORR)
Time frame: From baseline through 24 months
Treatment Completion Rate
Time frame: Up to 18 months
Local Control Rate
Time frame: Up to 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Background: PubMed 36623605Wang Y, Zhang T, Wang J, Zhou Z, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Ma X, Xue Q, Wang J, Wang Z, Bi N. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):590-600. doi: 10.1016/j.ijrobp.2022.12.042. Epub 2023 Jan 7.
- BackgroundHeymach JV, Harpole D, Mitsudomi T ea. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. 2023 AACR Annual Meeting; April 14-19, 2023; Orlando, FL 2023;
- Background: PubMed 37922691Wang C, Chen KN, Chen Q, Wu L, Wang Q, Li X, Ying K, Wang W, Zhao J, Liu L, Fu J, Zhang C, Liu J, Hu Y, Ntambwe I, Cai J, Bushong J, Tran P, Lu S. Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816. ESMO Open. 2023 Dec;8(6):102040. doi: 10.1016/j.esmoop.2023.102040. Epub 2023 Nov 1.
- Background: PubMed 34086039Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. Online ahead of print.
- Background: PubMed 35038429Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.
- Background: PubMed 35108059Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Ozguroglu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2.
- Background: PubMed 21903745Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. doi: 10.1093/jnci/djr325. Epub 2011 Sep 8.
- Background: PubMed 33538338Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
- Individual participant dataSharing planned: No
Related trials for Non-Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Induction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT) and consolidation immunotherapy in people with Non-Small Cell Lung Cancer and Locally Advanced Non-Small Cell Lung Cancer, run by Shanghai Chest Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Wen Yu, MD (021-22200000-3203, yuzhiwen0827@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Grade 3 or Higher Treatment-Related Adverse Events (time frame: From treatment initiation through 6 months after completion of radiotherapy). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07632365, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.